Valproate-induced insulin resistance and obesity in children

Hormone Research

Volumn 71, Issue 3, 2009, Pages 125-131

  Verrotti, Alberto ^a   La Torre, Rosanna ^a   Trotta, Daniela ^a   Mohn, Angelika ^a   Chiarelli, Francesco ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Epilepsy; Insulin resistance; Leptin; Obesity; Valproate

Indexed keywords

ANTICONVULSIVE AGENT; GLUCOSE; INSULIN; LEPTIN; LITHIUM; LONG CHAIN FATTY ACID; VALPROIC ACID;

ANTHROPOMETRIC PARAMETERS; BIOAVAILABILITY; BIPOLAR DISORDER; CELL STIMULATION; CLINICAL FEATURE; DRUG INDUCED DISEASE; ENDOCRINE DISEASE; EPILEPSY; GLUCOSE TRANSPORT; HORMONAL REGULATION; HORMONE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; HYPERLEPTINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; METABOLIC DISORDER; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PUBERTY; SEX DIFFERENCE; SHORT SURVEY; SIDE EFFECT; TREATMENT DURATION; WEIGHT GAIN;

ANTICONVULSANTS; CHILD; EPILEPSY; HUMANS; INSULIN RESISTANCE; OBESITY; VALPROIC ACID; WEIGHT GAIN;

EID: 59749102041     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000197868     Document Type: Short Survey

References (64)

1. Davis R, Peters DH, McTavish D: Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1994;47:332-372.
2. Klapper J: Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997;17:103-108.
3. Egger J, Brett EM: Effects of sodium valproate in 100 children with special reference to weight. BMJ 1981;283:577-580.
4. Verrotti A, Basciani F, Morresi S, de Martino M, Morgese G, Chiarelli F: Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology 1999;53:230-232.
5. Novak GP, Maytal J, Alshansky A, Eviatar L, Sy-Kho R, Siddique Q: Risk of excessive weight gain in epileptic children treated with valproate. J Child Neurol 1999;14:490-495.
6. Rattya YA, Vainionpaa L, Knip M, Lanning P, Isojarvi JI: The effects of valproate, carbamazepine and oxcarbamazepine on growth and sexual maturation in girls with epilepsy. Pediatrics 1999;103:588-593.
7. Demir E, Aysun S: Weight gain associated with valproate in childhood. Pediatr Neurol 2000;22:361-364.
8. Stephen LJ, Kwan P, Shapiro D, Dominiczak M, Brodie MJ: Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy. Epilepsia 2001;42:1002-1006.
9. Biton V, Mirza W, Montouris G, Vuong A, Hammer AE, Barrett PS: Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001;56:172-177.
10. Verrotti A, Basciani F, De Simone M, Trotta D, Morgese G, Chiarelli F: Insulin resistance in epileptic girls who gain weight after therapy with valproic acid. J Child Neurol 2002;17:256-258.
11. Pylvanen V, Knip M, Pakarinen A, Kotila M, Turkka J, Isojarvi JI: Serum insulin and leptin levels in valproate-associated obesity. Epilepsia 2002;43:514-517.
12. Luef G, Abraham I, Trinka E, Alge A, Windisch J, Daxenbichler G, Unterberger I, Seppi K: Hyperandrogenism, postprandial hyperinsulinism and the risk of PCOS in a cross-sectional study of women with epilepsy treated with valproate. Epilepsy Res 2002;48:91-102.
13. Elaine C, Wirrell MD: Valproic acid-associated weight gain in older children and teens with epilepsy. Pediatr Neurol 2003;28:126-129.
14. Pylvänen V, Knip M, Pakarinen AJ, Turkka J, Kotila M, Rattya J, Myllyla VV, Isojärvi JIT: Fasting serum insulin and lipid levels in men with epilepsy. Neurology 2003;60:571-574.
15. Biton V: Effect of antiepileptic drugs on body weight: overview and clinical implications for the treatment of epilepsy. CNS Drugs 2003;17:781-791.
16. Mikkonen K, Knip M, Pakarinen AJ, Lanning P, Isojärvi JIT, VainionpääLK: Growth and lipid metabolism in girls and young women with epilepsy during pubertal maturation. Epilepsia 2005;46:1114-1120.
17. Pylvänen V, Pakarinen A, Knip M, Isojärvi JIT: Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. Epilepsy Behav 2006;8:643-648.
18. De Vries L, Karasik A, Landau Z, Phillip M, Kiviti S, Goldberg-Stern H: Endocrine effects of valproate in adolescent girls with epilepsy. Epilepsia 2007;48:470-477.
19. El-Khatib F, Rauchenzauner M, Lechleitner M, Hoppichler F, Naser A, Waldmann M, Trinka E, Unterberger I, Bauer G, Luef G: Valproate, weight gain and carbohydrate craving: a gender study. Seizure 2007;16:226-232.
20. Prabhakar S, Sahota P, Kharbanda PS, Siali S, Jain V, Lal V, Khurana D: Sodium valproate, hyperandrogenism and altered ovarian function in Indian women with epilepsy: a prospective study. Epilepsia 2007;48:1371-1377.
21. Isojärvi JIT, Laatikainen TJ, Knip M, Pakarinen AJ, Juntunen KTS, Myllyla VV: Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39:579-584.
22. Dinesen H, Gram L, Andersen T, Dam M: Weight gain during treatment with valproate. Acta Neurol Scand 1984;69:65-69.
23. Zimmermann U, Kraus T, Himmerich H, Schuld A, Pollmacher T: Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 2003;37:193-220.
24. Isojärvi JIT, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllyla VV: Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993;329:1383-1388.
25. El-Khayat HA, Abd El-Basset FZ, Tomoum HY, Tohamy SM, Zaky AA, Mohamed MS, Hakky SM, El Barbary NS, Nassef NM: Physical growth and endocrinal disorders during pubertal maturation in girls with epilepsy. Epilepsy 2004;45:1106-1115.
26. Vainionpaa LK, Rattya J, Knip M, Tapanainen JS, Pakarinen AJ, Lanning P, Tekay A, Myllyla VV, Isojärvi JI: Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann Neurol 1999;45:444-450.
27. Caksen H, Deda G, Berberoglu M: Does long-term use of valproate cause weight gain in pre-pubertal epileptic children? Int J Neurosci 2002;112:1183-1189.
28. Tan H, Orbak Z, Kantarci M, Kocak N, Karaca L: Valproate-induced insulin resistance in prepubertal girls with epilepsy. J Pediatr Endocrinol Metab 2005;18:985-989.
29. Luef G, Abraham I, Hoppichler F, Trinka E, Unterberger I, Bauer G, Lechleitner M: Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy. Metabolism 2002;51:1274-1278.
30. Covanis A, Gupta AK, Jeavons PM: Sodium valproate: monotherapy and polytherapy. Epilepsia 1982;23:693-720.
31. Isojärvi JIT, Rattya J, Myllyla VV, Knip M, Koivunen R, Pakarinen AJ, Tekay A, Tapanainen JS: Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998;43:446-451.
32. Van den Pol AN: Weighing the role of hypothalamic feeding neurotransmitters. Neuron 2003;40:1059-1061.
33. Lakhanpal D, Kaur G: Valproic acid alters GnRH-GABA interactions in cycling female rats. Cell Mol Neurobiol 2007;27:1069-1083.
34. Tringali G, Aubry JM, Moscianese K, Zamori C, Vairano M, Preziosi P, Navarra P, Pozzoli G: Valproic acid inhibits corticotropin-releasing factor synthesis and release from the rat hypothalamus in vitro: evidence for the involvement of GABAergic neurotransmission. J Psychiatry Neurosci 2004;29:459-466.
35. Gilmor ML, Skelton KH, Nemeroff CB, Owens MJ: The effects of chronic treatment with the mood stabilizers valproic acid and lithium on corticotropin-releasing factor neuronal systems. J Pharmacol Exp Ther 2003;305:434-439.
36. Loiseau P: Review of controlled trials of Gabitril (tiagabine): a clinician's viewpoint. Epilepsia 1999;40:14-19.
37. Zhang Y, Proenca R, Maffei M: Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-431.
38. Campfield LA, Smith FJ, Burn B: The OB protein (leptin) pathway: a link between adipose tissue mass and central neural networks. Horm Metab Res 1996;28:619-632.
39. Halaas JL, Gafiwala KS, Mafei M,: Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995;269:543-546.
40. Smith FJ, Campfield LA, Moschera JA: Feeding inhibition by neuropeptide Y. Nature 1996;382:387.
41. Considine RV, Shina MK, Heiman ML: Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292-295.
42. Banks WA, Niehoff ML, Martin D, Farrell CL: Leptin transport across the blood-brain barrier of the Koletsky rat is not mediated by a product of the leptin receptor gene. Brain Res 2002;950:130-136.
43. Sahu A: A hypothalamic role in energy balance with special emphasis on leptin. Mini-review. Endocrinology 2004;145:2613-2620.
44. Segal KR, Landt M, Klein S: Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes 1996;45:988-991.
45. Patel SB, Reams GP, Spear RM, Freeman RH, Villarreal D: Leptin: linking obesity, the metabolic syndrome, and cardiovascular disease. Curr Hypertens Rep 2008;10:131-137.
46. Ren J: Leptin and hyperleptinemia from friend to for cardiovascular function. J Endocrinol 2004;181:1-10.
47. Zimmet P, Boyco EJ, Collier GR, de Courten M: Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players. Ann NY Acad Sci 1999;892:25-44.
48. Crowley VE: Overview of human obesity and central mechanisms regulating energy homeostasis. Ann Clin Biochem 2008;45:245-255.
49. Wilding JP: Neuropeptides and appetite control. Diabet Met 2002;19:619-627.
50. Lagace DC, McLeod RS, Nachtigal MW: Valproic acid inhibits leptin secretion and reduces leptin messenger ribonucleic acid levels in adipocytes. Endocrinology 2004;145:5493-5503.
51. Gil-Campos M, Canete R, Gil A: Adiponectin, the missing link in insulin resistance and obesity. Clin Nutr 2004;23:963-974.
52. Greco R, Latini G, Chiarelli F, Iannetti P, Verrotti A: Leptin, ghrelin, and adiponectin in epileptic patients treated with valproic acid. Neurology 2005;65:1808-1809.
53. Qiao L, Schaack J, Shao J: Suppression of adiponectin gene expression by histone deacetylase inhibitor valproic acid. Endocrinology 2006;147:865-874.
54. Klein KM, Hamer HM, Reis J, Schmidtke J, Oertel WH, Theisen FM, Hebebrand J, Rosenow F: Weight change in monozygotic twins treated with valproate. Obes Res 2005;13:1130-1134.
55. Corman CL, Leung NM, Guberman AH: Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Can J Neurol Sci 1997;24:240-244.
56. Keskin M, Kurtoglu S, Kendirci M, Atabek ME, Yazici C: Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 2005;115:500-503.
57. Conwell LS, Trost SG, Brown WJ, Batch JA: Indexes of insulin resistance and secretion in obese children and adolescents. Diabetes Care 2004;27:314-319.
58. Cutfield WS, Jefferies CA, Jakson WE, Robinson EM, Hofman PL: Evaluation of HOMA and QUIKI as measures of insulin sensitivity in prepubertal children. Pediatr Diabetes 2003;4:119-125.
59. Haymond MW: Measuring insulin resistance: a task worth doing. But how? Pediatr Diabetes 2003;4:115-118.
60. McIntyre RS, Mancini DA, McCann S, Srinivasan J, Kennedy SH: Valproate, bipolar disorder and polycystic ovarian syndrome. Bipolar Disord 2003;5:28-35.
61. Pylvanen V, Pakarinen A, Knip M, Isojärvi JIT: Characterization of insulin secretion in valproate-treated patients with epilepsy. Epilepsia 2006;47:1460-1464.
62. Haag M, Dippenaar NG: Dietary fats, fatty acids and insulin resistance: short review of a multifaceted connection. Med Sci Monit 2005;11:359-367.
63. Wong HY, Chu TS, Lai JC, Fung KP, Fok TF, Fujii T, Ho YY: Sodium valproate inhibits glucose transport and exacerbates Glut-1 deficiency in vitro. J Cell Biochem 2005;96:775-785.
64. Luef GJ, Lechleitner M, Bauer G, Trinka E, Hengster P: Valproic acid modulates islet cell insulin secretion: a possible mechanism of weight gain in epilepsy patients. Epilepsy Res 2003;55:53-58.